Sign in
4

Changes in Ownership

C4 Therapeutics, Inc. Filed Acc 0001662579-25-000019

Chief Business Officer sold 1,159 shares at $3.15 ($3,651)

  • Chief Business Officer gave up 4,103 shares (to pay taxes)
  • Chief Business Officer acquired 56,500 shares (grant or award)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Boyle Scott N · Chief Business Officer

Table I: Non-derivative

5 lines
Date Transaction Shares Price Value Owned after D/I
2025-02-13 Shares withheld for taxes : show line 1 in the form 10b5-1 −1,735 $3.20 $5,552 54,832 D
2025-02-14 Grant or award : show line 2 in the form 10b5-1 +56,500 111,332 D
2025-02-14 Sale : show line 3 in the form 10b5-1 −490 $3.15 $1,544 110,842 D
2025-02-14 Shares withheld for taxes : show line 4 in the form 10b5-1 −2,368 $3.18 $7,530 108,474 D
2025-02-18 Sale : show line 5 in the form 10b5-1 −669 $3.15 $2,107 107,805 D
Open-market sales · 1,159 sh · avg $3.15 · $3,651

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2025-02-14 Grant or award : show line 6 in the form 10b5-1 Stock Option (Right to Buy) +84,700 84,700 D
Loading xslF345X05/wk-form4_1739915710.xml…